STAAR Surgical Company - 10-K Summary (Fiscal Year Ended Dec 28, 2007)
Business Context and Reporting Period
Company: STAAR Surgical Company (STAAR)
Reporting Period: Fiscal year ended December 28, 2007
Business Overview: STAAR develops, manufactures, and sells visual implants and ophthalmic products, primarily foldable intraocular lenses (IOLs) for cataract surgery and implantable Collamer lenses (ICLs) for refractive surgery. The company operates globally with manufacturing facilities in the U.S., Switzerland, and Japan, and a distribution subsidiary in Germany (Domilens).
Key Event: On December 29, 2007 (subsequent to year-end), STAAR acquired the remaining 50% interest in its Japanese joint venture, Canon Staar, making it a wholly-owned subsidiary (STAAR Japan, Inc.).
Key Financial Metrics
| Metric (in thousands) | 2007 | 2006 |
|---|---|---|
| Net Sales | $59,363 | $56,951 |
| Gross Profit | $29,266 | $26,150 |
| Gross Margin | 49.3% | 45.9% |
| Operating Loss | $(14,119) | $(13,602) |
| Net Loss | $(15,999) | $(15,044) |
| Loss Per Share (Basic/Diluted) | $(0.57) | $(0.60) |
| Cash and Equivalents (End of Period) | $10,895 | $7,758 |
| Working Capital | $21,006 | $14,363 |
| Notes Payable (Long-term) | $4,166 | $0 |
Cash Flow: Net cash used in operating activities was $11.2 million in 2007, compared to $8.1 million in 2006. Financing activities provided $18.7 million, primarily from a public equity offering ($16.6 million) and a new $5 million loan from Broadwood Partners.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.2% to $59.4 million. This was driven by a 16% increase in international sales (particularly refractive products), which offset a 13.4% decline in U.S. sales.
- U.S. Market Decline: U.S. cataract sales dropped 15.5% due to market shifts toward aspheric lenses (where competitors led) and disruption from a U.S. sales force restructuring. U.S. refractive sales were flat.
- International Growth: International refractive sales grew 40% to $11.4 million. International cataract sales grew 8.3%.
- Margin Expansion: Gross margin improved to 49.3% from 45.9%, aided by reduced inventory reserves, higher selling prices for ICLs/TICLs, and improved IOL costs.
- Debt Structure: The company incurred a new $5 million senior promissory note in December 2007 to fund the acquisition of the Japanese joint venture.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy:
- Management aims to reverse U.S. cataract sales declines through new aspheric and Toric IOL introductions and a reorganized sales force.
- Profitability is expected to depend on increased U.S. sales of the Visian ICL and cost reduction initiatives targeting $3.5 million in annualized savings.
- The company does not expect to achieve positive consolidated cash flow in fiscal 2008 but believes current cash balances are sufficient through Q1 2009.
- TICL Approval Hold: The FDA placed the Toric ICL (TICL) application on "integrity hold" in August 2007 due to clinical oversight deficiencies. An independent third-party audit of patient records and clinical systems is underway. Approval is significantly delayed.
- Reputational Harm: Past FDA warning letters regarding quality systems and clinical oversight continue to impact U.S. sales and market perception.
- Former RMR Litigation: Two former regional manufacturer representatives (Moody and Parallax) sued for $32 million and $48 million respectively, alleging interference with contracts. STAAR denies the claims, filed cross-complaints, and has not reserved funds, though an adverse outcome could be material.
- Domilens Fraud: A prior investigation into fraud by the former president of the German subsidiary (Domilens) resulted in a material weakness in internal controls, which management states has been remediated.
- Single-Source Suppliers: Critical raw materials (silicone, collagen) are single-sourced; disruption could halt production.
- Currency Fluctuation: 67% of revenue is international; a stronger U.S. dollar negatively impacts reported sales.
Key Facts for Investor Verification
- U.S. Sales Trajectory: Verify if the restructured U.S. sales force and new aspheric/Toric product launches are successfully reversing the 16% decline in U.S. cataract sales.
- FDA TICL Status: Monitor the progress of the independent third-party audit required by the FDA to lift the "integrity hold" on the Toric ICL application, a key driver for future U.S. refractive growth.
- Cash Burn Rate: Assess whether the $3.5 million cost-cutting measures are sufficient to reduce the operating cash burn, given the company's history of losses and limited working capital.
- Japanese Integration: Evaluate the financial impact and integration progress of the newly acquired STAAR Japan subsidiary, which consolidates the Preloaded Injector business.
- Legal Exposure: Track the status of the Moody and Parallax lawsuits to determine if a material loss reserve will be required.